Wagner Isabella V, Ang Bryan, Checo Leticia, Simsek Derya, Draper Christian, Dorairaj Syril
Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.
Department of Ophthalmology, Tan Tock Seng Hospital, Singapore.
Clin Ophthalmol. 2023 Jun 2;17:1557-1564. doi: 10.2147/OPTH.S388293. eCollection 2023.
Minimally invasive glaucoma surgery (MIGS) has revolutionized glaucoma care with its favorable safety profile and ability to delay or minimize the need for traditional, bleb-based procedures. Microstent device implantation is a type of angle-based MIGS, which reduces intraocular pressure (IOP) through bypass of the juxtacanalicular trabecular meshwork (TM) and facilitation of aqueous outflow into the Schlemm's canal. Although there are limited microstent devices on the market, multiple studies have evaluated the safety and efficacy of iStent (Glaukos Corp.), iStent Inject (Glaukos Corp.), and Hydrus Microstent (Alcon) in the treatment of mild-to-moderate open-angle glaucoma, with and without concurrent phacoemulsification. This review attempts to provide a comprehensive evaluation of injectable angle-based microstent MIGS devices in the treatment of glaucoma.
微创青光眼手术（MIGS）凭借其良好的安全性以及延迟或减少对传统滤过泡手术需求的能力，彻底改变了青光眼的治疗方式。微支架装置植入是一种基于房角的MIGS，它通过绕过近管小梁网（TM）并促进房水流入施莱姆管来降低眼压（IOP）。尽管市场上的微支架装置有限，但多项研究评估了iStent（Glaukos公司）、iStent Inject（Glaukos公司）和Hydrus微支架（爱尔康）在治疗轻度至中度开角型青光眼（无论是否同时进行超声乳化白内障吸除术）方面的安全性和有效性。本综述旨在对用于治疗青光眼的可注射房角微支架MIGS装置进行全面评估。
